Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API High Quality

Short Description:

Product Name: Molnupiravir (EIDD-2801)

CAS: 2349386-89-4

Appearance: White to Off-White Powder 

Molnupiravir (EIDD-2801) COVID-19 Inhibitor

API High Quality, Commercial Production


Product Detail

Related Products

Product Tags


Commercial Supply Molnupiravir and Related Intermediates with High Quality
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4

Chemical Properties:

Chemical Name Molnupiravir (EIDD-2801)
Synonyms MK-4482; β-D-N4-Hydroxycytidine-5′-isopropyl ester; ((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
CAS Number 2349386-89-4
CAT Number RF-API97
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C13H19N3O7
Molecular Weight 329.31
Solubility Soluble in DMSO
Brand Ruifu Chemical


Item Specifications
Appearance White to Off-White Powder
Identification IR Sample Spectrum corresponds to that of reference standard
Identification HPLC The retention time of the major peak of the sample solution corresponds to that of the standard solution
Related Substances  
Impurity A ≤0.15%
Impurity B ≤0.15%
Any Unspecified Impurity   ≤0.15%
Total Unspecified Impurities ≤0.30%
Total Impurities ≤0.50%
Residual Solvents  
N-Heptane ≤5000ppm
Ethanol ≤5000ppm
Isopropyl Acetate ≤5000ppm
Acetonitrile ≤410ppm
Methylene Dichloride ≤600ppm
Acetone ≤5000ppm
Isopropanol ≤5000ppm
Water Content (K.F) ≤0.50%
Residue on Ignition ≤0.10% 
Optical Rotation -7.5° to -9.5° (C=0.5, Methanol)
Heavy Metals ≤10ppm
Purity / Analysis Method ≥99.5% (230nm)
Assay / Analysis Method 98.0%~102.0% (HPLC on dried basis)
Shelf Life 24 Months
Test Standard Enterprise Standard
Usage API, Molnupiravir (EIDD-2801) COVID-19 Inhibitor

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.





Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19. Molnupiravir is sold under the brand name Lagevrio and generically as emorivir. Molnupiravir has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, Molnupiravir, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. Molnupiravir was originally developed to treat influenza at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE), but was reportedly abandoned for mutagenicity concerns. It was then acquired by Miami-based company Ridgeback Biotherapeutics, which later partnered with Merck & Co. to develop the drug further. Molnupiravir was approved for medical use in the United Kingdom in November 2021.

  • Write your message here and send it to us